Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062699 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2,200
- Enrollment target
NCT00062699: Clinical Trial Phase 4 study, sponsored by Abbott.
NCT00062699 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 2,200 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (325% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062699, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2,200 participants
- Enrollment target
Study Summary
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
Interventions
- DRUG Zemplar (paricalcitol injection)
- DRUG Calcijex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2003-04 |
| Phase | Phase 4 |
Why NCT00062699 stopped before completion
NCT00062699 is an interventional study that assigns participants to a tested intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (325% higher).
The record links to 0 conditions, and to 2 interventions - of which Zemplar (paricalcitol injection) is the first listed.
NCT00062699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00062699 about?
NCT00062699 is a clinical study titled "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis". To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
What is the current status of trial NCT00062699?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2,200 participants. The study started on 2003-04.
What interventions are being tested in trial NCT00062699?
The interventions under investigation include: Zemplar (paricalcitol injection) (DRUG), Calcijex (DRUG).
Who is sponsoring clinical trial NCT00062699?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00062699's enrollment target sits among peer trials
2,200 32nd of 2000 higher than 1,969 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia